Core Viewpoint - The announcement outlines the restrictions on the exercise period for stock options granted by Zhejiang Yonghe Refrigeration Co., Ltd., detailing specific dates and conditions for the exercise of these options [1][2]. Group 1 - The company’s first grant of stock options (option code: 0000000868) entered its third exercise period on January 24, 2025, with an exercise validity period from January 24, 2025, to November 4, 2025 [1]. - The reserved stock options (option code: 1000000250) entered their second exercise period on October 16, 2024, with an exercise validity period from October 16, 2024, to September 1, 2025 [1]. - A restriction on the exercise period will be in effect from May 30, 2025, to June 25, 2025, during which all incentive recipients will be prohibited from exercising their options [2]. Group 2 - The company will apply to the China Securities Depository and Clearing Corporation Limited Shanghai Branch for the necessary procedures related to the restriction on the exercise of stock options [2].

Group 1 - The company has completed the cancellation of stock options and repurchase of restricted stocks as part of the 2022 incentive plan due to unmet performance targets for the third exercise period [2][3] - A total of 7.916 million stock options granted to 311 incentive recipients have been canceled, along with additional cancellations due to changes in employment status of certain recipients [2] - The cancellation of stock options will not affect the company's total share capital or financial results, ensuring no harm to the interests of shareholders, especially minority shareholders [3] Group 2 - The company has submitted the application for the cancellation of the stock options to the China Securities Depository and Clearing Corporation Limited, which has been confirmed and completed [3] - The cancellation process adheres to relevant laws, regulations, and the company's articles of association, ensuring compliance with the 2022 incentive plan [3]

证券代码：002456 证券简称：欧菲光 公告编号：2025-048 券报》《上海证券报》《证券日报》披露的《关于注销公司 2024 年第一期限制性 股票与股票期权激励计划部分股票期权的公告》（公告编号：2025-046）。 针对上述需注销的股票期权，公司已向中国证券登记结算有限责任公司深圳 分公司提交了注销申请。经中国证券登记结算有限公司深圳分公司审核确认，上 述股票期权的注销事宜已于近日办理完毕。 公司本次注销部分股票期权符合《上市公司股权激励管理办法》 《2024 年第 欧菲光集团股份有限公司 关于公司 2024 年第一期限制性股票与股票期权激励 计划部分股票期权注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 欧菲光集团股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日召开第 六届董事会第七次（临时）会议和第六届监事会第六次（临时）会议，审议通过 了《关于注销公司 2024 年第一期限制性股票与股票期权激励计划部分股票期权 。鉴于：公司 2024 年第一期限制性股票与股票期权激励计划 86 名股票 的议案》 期权激励对象因 ...

Core Viewpoint - The announcement details the verification and public disclosure of the reserved grant portion of the 2024 stock option incentive plan for Shandong Bangji Technology Co., Ltd, confirming that all listed incentive objects meet the necessary legal and regulatory qualifications [1][2][3] Disclosure Situation - The company publicly announced the list of incentive objects and provided a 10-day period for employees to raise any objections regarding the proposed incentive recipients [1] - No objections were received from employees by the end of the public disclosure period [2] Supervisory Board Verification Opinion - The supervisory board conducted a verification of the incentive object list according to relevant regulations and confirmed that all individuals listed meet the qualifications set forth by the Company Law and other applicable regulations [2] - The verification process ensured that none of the listed individuals had been deemed inappropriate candidates by the securities exchange or the China Securities Regulatory Commission within the last 12 months, nor had they faced any significant legal penalties [2][3] - The supervisory board concluded that all individuals on the incentive object list are legally and effectively qualified to participate in the stock option incentive plan [3]

关于2024年股票期权激励计划第一个行权期行权条件成就的公告 乐心医疗2025年公告，证券代码：300562，公告编号：2025-048。公司2024年股票期权激励计划第一个 行权期行权条件成就，33名激励对象符合行权条件，涉及82.25万份股票期权，占公司总股本的0.38%， 行权价格为8.73元/份。 关于2024年员工持股计划第一个锁定期解锁条件成就的公告 截至2025年5月23日收盘，乐心医疗（300562）报收于13.98元，较上周的14.55元下跌3.92%。本周，乐 心医疗5月19日盘中最高价报14.72元。5月23日盘中最低价报13.96元。乐心医疗当前最新总市值30.4亿 元，在医疗器械板块市值排名98/126，在两市A股市值排名4092/5148。 本周关注点 公司公告汇总信息披露管理制度(2025年05月） 广东乐心医疗电子股份有限公司信息披露管理制度旨在规范公司信息披露行为，保护投资者合法权益。 信息披露义务人应真实、准确、完整、及时披露信息，不得有虚假记载、误导性陈述或重大遗漏。公司 董事、高级管理人员应忠实、勤勉履行职责，确保信息质量。内幕信息在依法披露前不得公开或泄露， 不得用于 ...

Group 1 - The company held its 20th meeting of the 4th Board of Directors on May 22, 2025, to discuss various proposals [2][3][4] - The meeting was attended by all 7 directors, and the resolutions passed were deemed legal and effective [4][5] - The company plans to distribute a cash dividend of RMB 0.09 per share for the fiscal year 2024, pending approval at the upcoming shareholder meeting [56][57][58] Group 2 - The company approved the cancellation of 50,000 stock options and the repurchase of 64,400 restricted stocks due to the departure of two incentive plan participants [9][24][28] - The repurchase price for the restricted stocks was adjusted from RMB 4.24 to RMB 4.15 per share [13][66][71] - The company will hold its first extraordinary general meeting of 2025 on June 9, 2025, to discuss the approved proposals [21][77][78] Group 3 - The company’s total share capital will decrease from 289,699,061 shares to 289,634,661 shares following the repurchase and cancellation of stocks [34][40][35] - The company’s registered capital will also be adjusted accordingly, reflecting the changes in share capital [34][40][35] - The adjustments to the company’s capital structure and the related proposals will be submitted for shareholder approval [20][21][38]

Group 1 - The company held its fourth board meeting on May 23, 2025, with all nine directors present, including two participating via communication methods [2][3][6] - The board approved the draft of the 2025 Employee Stock Ownership Plan and its management measures, which will be submitted for shareholder approval [3][8][19] - The board also approved the draft of the 2025 Stock Option Incentive Plan and its management measures, which aim to enhance the company's governance structure and motivate key personnel [19][23][28] Group 2 - The board proposed to hold the second extraordinary general meeting of shareholders on June 9, 2025, to review the approved proposals [32][52] - The board approved an increase in the estimated external guarantee limit for 2025 by RMB 35 million, bringing the total to RMB 300 million for subsidiaries [34][70][71] - The company confirmed that as of April 30, 2025, the total external guarantees amounted to RMB 1.385 billion, representing 14.19% of the latest audited net assets [77]

证券代码：605099 证券简称：共创草坪 公告编号：2025-019 江苏共创人造草坪股份有限公司 关于 2024 年股票期权与限制性股票激励计划股票期 权预留部分第二次授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ? 股票期权登记日：2025 年 5 月 23 日 ? 股票期权登记数量：35,000 份 根据《上市公司股权激励管理办法》（以下简称《管理办法》）、江苏共创 人造草坪股份有限公司（以下简称"公司"）《2024 年股票期权与限制性股票 激励计划（草案）》（以下简称《激励计划》）的有关规定，公司已于 2025 年 票期权与限制性股票激励计划之股票期权预留部分的第二次授予登记工作，现将 有关事项说明如下： 一、股票期权授予情况 第八次会议，均审议通过《关于 2024 年股票期权与限制性股票激励计划预留部 分第二次授予的议案》。根据《管理办法》《激励计划》的有关规定及公司 2024 年第二次临时股东大会的授权，董事会认为公司 2024 年股票期权与限制性股票 激励计划规定的预留授予 ...

湖南启元律师事务所 关于 湖南科力远新能源股份有限公司 法律意见书 二〇二五年五月 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410000 电话：（0731）8295 3778 传真：（0731）8295 3779 致：湖南科力远新能源股份有限公司 湖南启元律师事务所（以下简称"本所"）接受湖南科力远新能源股份有限 公司（以下简称"公司"、"科力远"）的委托，作为特聘专项法律顾问为公司 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股 权激励管理办法》（以下简称"《管理办法》"）等相关法律、法规、规范性文件及 公司章程、《湖南科力远新能源股份有限公司 2025 年股票期权激励计划（草案）》 （以下简称"《激励计划（草案）》"）的规定，按照律师行业公认的业务标准、道 德规范和勤勉尽责精神，对本次激励计划授予激励对象人数调整（以下简称"本 次调整"，）及股票期权首次授予（以下简称"本次授予"）相关事项（以下合称 "本次调整及授予"）所涉及的有关事实进行了核查和验证，出具本法律意见书。 为出具本法律意见书，本所特作如下声明： （一）本所律师依据《中华人民共和国证券法》（ ...

Core Viewpoint - The announcement details the results of the second exercise period of the 2022 stock option incentive plan for Hangzhou Zongheng Communication Co., Ltd, including the number of shares listed and the exercise process [1][2][3]. Group 1: Stock Option Incentive Plan - The stock option incentive plan involves the issuance of 90,000 shares, with the listing date set for May 29, 2025 [1]. - The plan was approved through a board meeting, with independent directors and the supervisory board providing their consent and verification [1][2]. - A total of 6.83 million stock options were granted to 49 incentive objects on the initial grant date, with 6.71 million options actually registered for 48 individuals [3]. Group 2: Exercise and Registration Details - The second exercise period saw one individual exercising 90,000 options, representing 1.12% of the total options granted and 0.04% of the total share capital before the exercise [6]. - The stock options were sourced from the company's directed issuance of A-shares to the incentive objects [6]. - The total number of shares before the exercise was 229,248,293, which increased to 229,338,293 after the exercise [7]. Group 3: Financial Impact and Fundraising - The funds raised from this exercise amounted to 1,076,400.00 RMB, which is not expected to significantly impact the company's financial status or operational results [8].